Conditions: Severe Pulmonary Arterial Hypertension
Keywords: Pulmonary arterial hypertension, QTI571, open label study
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: no

Brief summary:
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.

Detailed description:
This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study (A2301E1) and were judged by the investigator to benefit from continued QTI571 treatment.

Arms:
arm 1: Participants will receive QTI571 during 3 years.

Interventions: intervention 1: QTI571
Intervention descriptions: intervention 1: QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.

Protocol document: